Jagsonpal Pharmaceuticals has set the record date for its 5:2 stock split for tomorrow, January 8, 2025. The announcement was made on October 23, 2024, with the ex-date scheduled for January 8, 2025.
On April 30, 2004, the company announced a 2:1 stock split, which took effect on July 20, 2004. This means for every share held by an investor, they received 2 shares after the split adjustment, effectively doubling the number of shares in circulation while maintaining the total value for shareholders.
In the second quarter of fiscal 2025, Jagsonpal Pharmaceuticals reported strong financial growth compared to Q2FY24. Revenues surged to ₹74.7 crore, marking a 29.2% increase from ₹57.8 crore in Q2FY24.
Operating EBITDA saw a significant rise of 46.0%, reaching ₹18.4 crore from ₹12.6 crore, driven by improved operational efficiency. The EBITDA margin also expanded by 280 basis points, reaching 24.6% in Q2FY25, up from 21.8% in the same quarter last year.
Net profit (PAT) saw a notable increase of 52.0%, standing at ₹11.4 crore, compared to ₹7.5 crore in Q2FY24, reflecting the company’s strong profitability during the period.
Jagsonpal Pharmaceuticals, founded over 5 decades ago, is an Indian healthcare company committed to delivering affordable and quality medical solutions globally. Jagsonpal’s mission is to create a global brand from India.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jan 7, 2025, 9:00 AM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
